Adial Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update
Conducted meetings with U.S. and select European regulatory agencies
Received Notice of Exercise and upfront cash of $0.45 million from Advocate for the sale of Purnovate assets and business
Related news for (ADIL)
- Adial Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update
- Adial Pharmaceuticals Completes Successful EOP2 FDA Meeting
- Today’s Top Performers: MoBot’s Market Review 07/29/25 08:00 AM
- Today’s Top Performers: MoBot’s Market Review 07/28/25 04:00 PM
- Don’t Miss Out: MoBot’s Latest Stock Updates 07/28/25 11:00 AM